Press Release October 01, 2018

Goodwin Names 22 New Partners

Global law firm Goodwin announced today that 22 lawyers have been elected to the firm’s partnership, effective October 1.

“Through their leadership and commitment to our clients, these exceptional lawyers have weaved themselves into the fabric of our firm,” said David Hashmall, Goodwin’s Chairman. “We are excited to welcome them to the partnership and look forward to their continuing contributions to Goodwin’s success.”

The newly elected partners include:

  • Sarah Ashfaq (Technology and Life Sciences; New York) counsels biotechnology, pharmaceutical, and other life sciences companies, providing strategic advice to management teams and boards while leading significant transactions on her clients’ behalf, including IPOs, follow-on offerings, and private placements of equity and debt securities. She also regularly represents investment banks in a broad array of financing transactions.
  • Jacqueline M. Bostel (Real Estate Industry; New York) represents clients in a variety of commercial real estate transactions, including complex joint ventures, restructurings and recapitalizations, mortgage, construction and mezzanine financings (for both borrowers and lenders), and asset-level and entity-level acquisitions and dispositions, and advises commercial real estate investment managers in establishing and managing other private investment vehicles such as commingled funds, separate accounts and club programs.
  • Charles A. Brown (Securities Litigation and White Collar Defense; New York) represents issuers, underwriters, and individuals in securities class actions, shareholder derivative actions, and criminal and regulatory proceedings. He also has extensive experience representing investment advisers in mutual fund litigation.
  • Dylan S. Brown (Private Equity; San Francisco) primarily represents private equity sponsors and private and public companies in structuring and negotiating secured and unsecured debt financing transactions, including leveraged buyouts, acquisition-financings, recapitalizations, refinancings, and restructurings. He has represented clients across a range of industries, including the technology, software, healthcare, financial services, manufacturing, and retail sectors.
  • Eric J. Carlson (Private Equity; Boston) represents private equity and venture capital firms, operating companies, and investors in a broad range of strategic transactions, including leveraged buyouts, carve-outs, exits, growth equity financings, and general corporate and governance matters.
  • Linnea P. Cipriano (IP Litigation; New York) focuses on patent litigation in federal courts, the International Trade Commission, and the U.S. Patent and Trademark Office’s Patent Trial and Appeal Board. She has prosecuted and litigated patents involving a broad range of technologies, including pharmaceuticals, biosimilars, nutritional supplements, DNA-based technology, and drug delivery technology.
  • Natasha E. Daughtrey (IP Litigation; Los Angeles) represents clients in all phases of intellectual property litigation from pre-litigation due diligence through appeal. She focuses on patent litigation, and has expertise across a broad range of technologies, including pharmaceuticals, medical devices, and biotechnology.
  • Noelle C. Dubiansky (Technology and Life Sciences; Washington, D.C.) represents biotechnology, pharmaceutical, medical device, and other life sciences companies in a wide range of intellectual property and commercial transactions, including strategic partnerships, licensing, technology acquisition, R&D collaborations, clinical testing, contract services, and distribution and manufacturing agreements.
  • Thomas Dupont-Sentilles (Private Equity; Paris) advises European and U.S. clients on a broad range of corporate law matters, including domestic and cross-border mergers and acquisitions, private equity deals and leveraged buyouts, venture capital investments, and management incentive schemes.
  • Amy D. Keller (Private Equity; San Francisco) advises private equity sponsors and private companies in a range of matters, including mergers, stock and asset acquisitions and divestitures, leveraged recapitalizations, minority and growth equity investments and joint ventures, and general corporate matters. She has represented clients across a range of industries, including technology, healthcare, manufacturing, financial services and education.
  • Lillian Kim (Technology and Life Sciences; New York) focuses her practice on advising public companies with respect to mergers and acquisitions and a variety of corporate governance matters. She represents clients from a wide range of industries, including technology, life sciences, financial services, retail and manufacturing.
  • Sarah Michel (Private Equity; Paris) advises on a range of international private investment funds: buyout, growth capital, venture/tech, real estate, infrastructure, fund of funds, mezzanine, and debt. She also has extensive experience structuring regulated portfolio management companies, carried-interest schemes for management teams, and strategic co-investments.
  • Michael Miranda (Private Equity; London) focuses his practice on domestic and cross-border private equity transactions, representing institutional investors, private companies, founders, and management teams on leveraged buyouts, growth capital, minority investments, and other corporate finance matters in sectors including healthcare, financial services, technology, retail, and leisure. 
  • Jason F. Monfort (Financial Industry; Washington, D.C.) represents investment companies, independent directors of registered investment companies, registered investment advisers, broker-dealers, private investment funds, insurance companies, and other financial institutions in the full spectrum of financial services regulation applicable to developing, marketing, and offering financial products.
  • Morgan Mordecai (Securities Litigation and White Collar Defense; Boston) concentrates on government and internal investigations, including civil and criminal investigations by the DOJ, SEC, and other regulatory agencies, M&A-related litigation, securities litigation, and complex business litigation matters. Her clients include public and private healthcare, life sciences, and technology companies, their boards and officers, private equity and venture capital firms, and financial services providers.
  • Jesse Nevarez (Technology and Life Sciences; New York) represents technology and life sciences companies, including those focused on software, hardware, digital media, advertising, biotechnology, pharmaceuticals, medical devices, and diagnostics. He regularly advises entrepreneurs, startups, emerging companies, and public companies on a variety of corporate matters from formation through initial public offering.
  • Jessica L. Rothstein (Technology and Life Sciences; New York) concentrates her practice on the counseling, protection, and licensing of intellectual property rights, with an emphasis on the worldwide protection of trademarks and global brand management.
  • Jonathan R. Scott (Private Equity; New York) advises clients with respect to broad-based general corporate and transactional matters with a particular focus on mergers and acquisitions, private equity, growth equity, and venture capital transactions. His clients include companies in the technology, media, financial services, insurance, energy, manufacturing, and sports and entertainment sectors.
  • Rachel M. Walsh (IP Litigation; San Francisco) focuses her practice on patent, trade secret, and other technology-related litigation. Her practice involves a variety of technologies, including semiconductors, medical devices, telecommunications, and biotechnology.
  • Bethany P. Withers (Technology and Life Sciences; Boston) concentrates on technology and intellectual property transactions. She works with a broad base of start-up, venture-backed, and growth companies, advising on protecting, licensing, acquiring, and selling intellectual property.
  • James Xu (Technology and Life Sciences; Boston) concentrates on capital markets transactions, with a focus on initial public offerings, as well as securities law reporting and compliance. He represents a wide variety of companies and investment banks in the technology and life sciences industries.
  • David J. Zimmer (Specialty Litigation - Appellate; Boston) focuses on appellate litigation, especially cases involving intellectual property, consumer financial services, and constitutional and regulatory issues. He has successfully argued cases in the U.S. Supreme Court and the Second and Ninth Circuit Courts of Appeals, and has drafted and contributed to briefs for cases before numerous other federal courts of appeals and district and state courts throughout the country.